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This review focuses on the anxiety related to cyclic AMP/protein kinase A (PKA) signaling 
pathway that regulates stress responses. PKA regulates an array of diverse signals that 
interact with various neurotransmitter systems associated with alertness, mood, and 
acute and social anxiety-like states. Recent mouse studies support the involvement of 
the PKA pathway in common neuropsychiatric disorders characterized by heightened 
activation of the amygdala. The amygdala is critical for adaptive responses leading to 
fear learning and aberrant fear memory and its heightened activation is widely thought 
to underpin various anxiety disorders. Stress-induced plasticity within the amygdala is 
involved in the transition from normal vigilance responses to emotional reactivity, fear 
over-generalization, and deficits in fear inhibition resulting in pathological anxiety and 
conditions, such as panic and depression. Human studies of PKA signaling defects 
also report an increased incidence of psychiatric disorders, including anxiety, depres-
sion, bipolar disorder, learning disorders, and attention deficit hyperactivity disorder. 
We speculate that the PKA system is uniquely suited for selective, molecularly targeted 
intervention that may be proven effective in anxiolytic therapy.
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OveRview OF THe PKA PATHwAY
Protein kinase A (PKA) is an inactive tetrameric holoenzyme consisting of two catalytic (C) subunits 
each bound to a regulatory (R) subunit dimer. The four R subunits RIα, RIβ, RIIα, and RIIβ, coded 
by different genes, characterize the subtypes PKA-I and -II (1). Different genes also code for the 
four catalytic (C) subunits Cα, Cβ, Cγ, and protein kinase X (PRKX), which are expressed (like the 
R subunits) in a cell- and tissue-specific manner (2). When the R and C subunits form the PKA 
tetramer (R2C2), there is no PKA catalytic activity. Additionally, R2C2 is bound and, thus, com-
partmentalized within the cell by A-kinase anchoring proteins (AKAPs) that direct PKA-signaling 
to specific cell regions and/or organelles (3).
Protein kinase A is considered the primary target for cyclic AMP (cAMP) in the cell, is widely dis-
tributed, and serves as the principal effector mechanism for G-protein-coupled receptors (GPCRs) 
linked to adenylate cyclase (4). The seven-transmembrane domain GPCRs sense molecules outside 
the cell and activate inside signal transduction pathways to induce cellular responses. The majority of 
receptors for proteins, biogenic amines, protons, hormones, neurotransmitters, and neuromodula-
tors elicit their responses through guanine nucleotide-binding proteins (G-proteins). The G-protein 
α subunits, encoded by 16 distinct genes, confer receptor–effector specificity to G-proteins. The 
γ subunits, encoded by 12 genes, have G protein-specific recognition sites and bind tightly to β 
FiGURe 1 | The PKA enzyme is central in the regulation of the cAMP-signaling pathway; for description, please see the text.
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subunits. The β subunits, encoded by five genes, also contain a 
common binding site for α subunit recognition. In their inactive 
state, the α and βγ subunits are bound to guanosine diphosphate 
(GDP) and can interact with effectors (Figure 1). This interaction 
releases GDP in an exchange with guanosine triphosphate (GTP) 
leading to the generation of α-GTP and a βγ subunit dimer (5, 
6). Of the various Gα isoforms, the activation of Gsα stimulates 
adenylyl cyclase resulting in the production of cAMP. By contrast, 
the Giα mediates the inhibition of adenylyl cyclase (7, 8).
The increased intracellular cAMP, serving as a second 
messenger, binds to the regulatory PKA subunits, leading to 
the disassociation of the tetrameric PKA holoenzyme into an 
R2-cAMP 4 dimer and two monomers of free catalytic subunits 
(9). Then, the PKA C subunits catalyze the transfer of phos-
phates from ATP to serine and threonine residues of targeted 
intracellular proteins modifying hormonal and neurotransmitter 
responses, desensitizing receptors related to cortisol biosynthesis, 
cell differentiation, and synaptic plasticity, and activating or 
repressing gene transcription (10–12). The principal target of 
C subunits that translocate to the nucleus is phosphorylation of 
cAMP-responsive nuclear factors (13) that regulate the expres-
sion of genes containing cAMP-responsive elements binding 
proteins (CREBs) (14) (Figure 1). Phosphorylated CREB binds 
to CRE nucleotide sequences in DNA as a dimer, recruiting 
CREB-binding protein (CBP) and p300 cofactors to form larger 
transcriptional complexes, and catalyzes histone acetylation 
regulating target genes. Activated CREBs coordinate various 
neuronal functions, development, and synaptic plasticity (15). 
Through a feedback mechanism, activated by RIα, cytosolic 
phosphodiesterases (PDEs) terminate the signals generated by 
cAMP by hydrolyzing cAMP into 5′AMP (16). As shown in 
knockout (KO) mouse studies, these four genes function in a 
3Keil et al. PKA Defects and Anxiety
Frontiers in Endocrinology | www.frontiersin.org June 2016 | Volume 7 | Article 83
tissue- and cell-type-specific manner to regulate accurately the 
activity of the C subunits (2).
CORTiCOTROPin-ReLeASinG 
HORMOne wiTH PKA
Corticotropin (ACTH)-releasing hormone (CRH)-induced 
intracellular increase in calcium and cAMP (and PKA activation) 
through binding to its seven-transmembrane receptor activates 
several transcription factors including CREB, c-fos, and JunB, 
which subsequently activate the pro-opiomelanocortin promoter 
(17). ιnnervation to CRH neurons is provided by fibers containing 
the pituitary adenylate cyclase-activating polypeptide (PACAP) 
(18). It is possible that stress induces secretion of PACAP in 
the paraventricular nucleus (PVN), thereby stimulating CRH 
gene expression via activation of the cAMP/PKA system (19). 
Especially, amygdala and lower brainstem contributions to the 
augmentation of the stress response have been identified as sites 
of pituitary PACAP innervation (19). Thus, CRH, released by 
stress signals, stimulates a pulsatile secretion of adrenocortico-
tropic hormone (ACTH) with peak levels seen before waking and 
declining at night.
Adrenocorticotropic hormone exerts its effects on the adrenal 
cortex by binding to a specific receptor (ACTHR) that is the 
melanocortin-2 receptor (MC2R, coded by the MC2R gene). 
MC2R is a GPCR linked to Gsα and, thus, ACTH binding triggers 
activation of adenylate cyclase that catalyzes the conversion of 
adenosine triphosphate to cAMP (20). The elevation of cAMP 
is followed by increased PKA activity at the adrenal cortex that 
results in increased steroidogenesis and the production of gluco-
corticoids (GCs). Negative feedback on pituitary ACTH secre-
tion is exerted by cortisol at both the hypothalamic and anterior 
pituitary levels. Importantly, hypothalamic cAMP-inducing CRH 
might also counterbalance excessive stimulatory stress effects on 
the hypothalamic–pituitary–adrenal (HPA) axis and maintain 
immuno-neuroendocrine homeostasis (21).
Other peptide hormones that are secreted and function in an 
endocrine manner also act as ligands and signal via a wide range 
of GPCRs. Such peptide hormones, mostly bind within the trans-
membrane domain, include the growth-regulating hormones 
somatostatins, parathyroid hormone, angiotensin, HCRTR2, 
oxytocin, calcitonin, C5a anaphylatoxin, cannabinoids, follicle-
stimulating hormone, gonadotropin-releasing hormone, neuro-
kinin, thyrotropin-releasing hormone, and the cholecystokinin 
peptide hormone system. GPCRs are responsive to hormones, 
calcium, and neurotransmitters allowing them to form the largest 
family of validated drug targets (22).
ROLe OF PKA in AnXieTY AnD FeAR 
LeARninG
This review focuses on the role of the cAMP-signaling pathway 
and its mediator, PKA, in the pathogenesis of disorders related 
to fear learning and anxiety. Anxiety disorders are associated 
with abnormalities in neural processing of threat-related stimuli 
(fear learning), which is regulated by cAMP/PKA pathway.
Preclinical studies provide evidence that the pathogenesis of 
mood disorders, such as anxiety and depression, involves altera-
tions in the plasticity of neuronal pathways (23, 24). Also, clinical 
studies demonstrate that chronic stress and depression alter 
brain structures (i.e., cell number and density, cell body size, 
neuronal and glial density in frontal cortical and hypothalamus) 
and that result in functional changes (25–29). In addition, studies 
of suicide subjects report alterations in levels of serotonin and 
norepinephrine, their metabolites, and receptors, in the brain 
and peripheral tissues, as well as intracellular signaling pathways 
(30, 31). Post-mortem studies demonstrate disruptions in cAMP/
PKA/CREB/Rap1/BDNF in the brains of suicide subjects that 
are modulated by stress and GCs (32). There is a paucity of data 
about PKA activity in brain areas other than the frontal cortex 
from post-mortem brains of depressed and suicidal subjects. The 
cAMP/PKA signaling pathway in the central nervous system is 
well-characterized and has a crucial role for various physiological 
responses that are important for cell survival, synaptic plasticity, 
and gene expression (33, 34). Alterations in synaptic and struc-
tural plasticity are associated with mood disorders, including 
generalized anxiety disorder, depression, and suicide.
PKA and Fear Learning and Memory
There is substantial evidence from different species (fruit fly, 
mouse, chick, and rat) to support the role of cAMP/PKA signaling 
in the molecular pathways related to fear and fear memory. The 
seminal work of Schacher, Kandel, and Abel demonstrated the 
essential role of the cAMP/PKA pathway in the response to fear 
and consolidation of fear memory (15, 35, 36). Consistent with the 
evolutionarily conserved role of the cAMP/PKA pathway, anxiety 
and fear responses are essential to survival. The mechanisms of 
PKA in fear memory are well established and include a wide range 
of cellular processes, including activation of cAMP–CREB and 
various other transcription factors involved in the regulation of 
de novo protein synthesis that is required for long-term memory 
formation. Signaling activity in neural circuits pre- or post-
stimuli may influence PKA activity and long-term potentiation 
(LTP), affecting fear learning and memory of the event (37–39). 
Also, there is a time-dependent activation profile in the kinase 
pathways involved in fear memory formation. PKA has two peaks 
of activity in the process of long-term memory formation, with 
the first occurring a few minutes after the event, and the second 
occurring 2 to 3  h after the event (requires both transcription 
and protein synthesis). The PKA pathway is also an important 
component of short-term memory within the first hour after the 
event. The phosphorylated form of CREB also increases at these 
same time periods as PKA and contributes to the synthesis of new 
proteins that are essential for long-term memory formation (40).
The cAMP–CREB element is ubiquitous in genes and functions 
as a promoter in many brain areas that respond to environmental 
stimuli. PKA signaling has been described as a “central hub” that 
interacts with varied other signaling pathways in neuroendocrine 
cells (41). PKA mediates and communicates cAMP effects to 
mitogen-activated protein kinases (MAPK) and protein kinase 
C (PKC) and B pathways. Signal transduction pathways, such 
as PKA and PKC, have important roles in the regulation of the 
HPA and autonomic nervous system (ANS) and, therefore, may 
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have a role in the expression of genes that contain cAMP in their 
promoters, which include key proteins that regulate the neuroen-
docrine stress response (i.e., brain-derived neurotrophic factor 
and GC receptor) (42).
Types of traumatic stress, which have been associated with 
maladaptive responses or psychopathology, include mass trauma, 
war, terrorism, natural or technological disasters, violent personal 
assaults, child abuse (physical, sexual, emotional), life-threatening 
illness, and accidents. However, not every person who is exposed 
to traumatic stress will develop long-lasting psychological 
morbidity, such as depression, anxiety, or post traumatic stress 
disorder. The development and/or severity of these conditions 
depends on multiple factors, including genetic pre-disposition to 
vulnerability, exposure to adverse environmental factors, and the 
timing of the stress exposure (43, 44).
Typically, the stress response has been identified as a “fight 
or flight” reaction, but may also include an increased state of 
vigilance, which is often accompanied by increased anxiety. The 
response to an environmental stressor involves the individual’s 
interpretation of the threat, which is regulated by the brain. 
The brain and nervous system demonstrate adaptive plasticity 
through local neurotransmitters and systemic hormones, which 
interact to produce structural and functional changes (45).
The brain is also a target for the actions of stress hormones, in 
particular, GCs. With stress exposure, the PVN in the hypothala-
mus releases CRH and arginine vasopressin, which stimulate the 
anterior pituitary to release ACTH, which stimulates the adrenal 
cortex to release GCs. GCs exert a negative feedback to the 
hypothalamus and anterior pituitary to downregulate the stress 
response through their receptor (GR) which is found expressed 
highly in the hippocampus, amygdala, and prefrontal cortex. This 
facilitates the formation of memories associated with strong emo-
tions particularly during stress.
PKA and Anxiety
Anxiety is an adaptive response to a potential threat that serves a 
protective function. However, pathological anxiety is associated 
with abnormalities in fear learning or threat detection (46–49) 
and a bias to interpret ambiguous situations as threatening with 
corresponding behavioral responses of avoidance or exaggerated 
reactions to potential threats (50). Fear memories can form quickly 
and be difficult to eliminate (51, 52). Evidence from experimental 
and preclinical studies provides support that anxiety disorders 
are associated with abnormal neural processing of threat-related 
stimuli, which is mediated by the PKA pathway.
The amygdala, located in the temporal lobe of the brain, has 
a crucial role in the processing and expression of emotional 
stimuli (53, 54). Prior studies with humans and laboratory 
animals provide evidence that novelty and fear-related stimuli 
are both processed by the amygdala (55–58). Hyperactivity of 
the amygdala as demonstrated by functional neuroimaging 
studies in humans, has been identified as a neural correlate 
for clinical symptoms seen in post traumatic stress disorder 
(59, 60), which suggests that amygdala dysfunction may be a 
risk factor for development of affective stress-related disorders 
(61). The basolateral amygdala is identified as a hub through 
which sensory information is relayed either directly or indirectly 
via the basal nucleus to the central amygdala (CEA), which is 
the major efferent source that directs fear-related behavioral 
response (51, 62).
The amygdala has a crucial role in the modulation of atten-
tion orientation to potential threats (63, 64). Activation of 
β-adrenoreceptors in the BLA enhances memory consolidation 
associated with fear via the stimulation of the cAMP/PKA path-
way (65). Lesion and agonist/antagonist studies demonstrate the 
critical role of the BLA in mediating the effects of stress hormones 
on memory consolidation of fear-related stimuli. During threat 
processing, the prefrontal cortex is also engaged, although more 
gradually than the brisk response of the amygdala, which allows 
flexible modulation of amygdala-based processing by providing a 
more detailed representation of threat attributes (63, 66). Ghosh 
and Chattarji (67) recently reported that targeted activation of 
cAMP–PKA signaling in the lateral amygdala led to generalized 
fear, which provides novel insight of the cellular basis in the 
amygdala for the alteration of emotional states from normal to 
pathological fear.
Naturally, the endogenous PKA inhibitor (PKI) peptide 
participates in the regulation of PKA by binding to the free 
catalytic PKA subunit, thus preventing phosphorylation of PKA 
targets in various tissues and cell types. In addition, PKA signal-
ing has been investigated using pharmacological PKIs, such as 
the H89 and KT5720 (68). These compounds, readily crossing 
the cell membranes, block PKA actions through competitive 
inhibition of the ATP site on the PKA catalytic subunit. Also, 
the introduction of a non-functioning PKA mutant, such as 
a dominant negative version of PKA into cells has allowed 
researchers to perturb specific signaling through PKA and to 
examine PKA’s role in cell anchorage and protein expression in 
epithelial cells (69). Transfection of cDNA prevents binding of 
the R subunits to AKAPs also preventing PKA signaling and 
its localization to specific cellular organelles. Finally, among a 
number of other existing methods, PKA activity and signaling 
has been investigated in mice with genetic manipulation of the 
PKA system. These studies have allowed for particular investiga-
tion of various aspects of PKA signaling in organic systems and 
areas, focusing on altered physiology in intact animals. It has 
been anticipated that, by producing physiological changes, these 
mouse models might profitably be modulated for therapeutic 
purposes.
eFFeCT OF inHiBiTiOn OF PKA PATHwAY 
On AnXieTY BeHAviOR
Studies using inhibitors or activators of PKA helped to elucidate 
its role in memory formation. Inhibition of protein synthesis 
or PKA activity blocks LTP in the hippocampus and interferes 
with memory consolidation for fear in the amygdala (70–72). 
Also, infusion of PKIs into basolateral amygdala immediately 
following fear-conditioning training dose-dependently blocked 
consolidation of fear memory (24-h post training) but not short-
term memory (4-h) (73). Infusion of inhibitor Rp-cAMP into 
the CEA decreased CREB function and decreased neuropeptide 
5Keil et al. PKA Defects and Anxiety
Frontiers in Endocrinology | www.frontiersin.org June 2016 | Volume 7 | Article 83
Y expression and provoked anxiety-like behavior and alcohol 
intake in non-preferring rats (74).
In addition, studies using PDE4 inhibitors help to elucidate 
the molecular mechanisms involved with the behavioral response 
(anxiolytic-like) to inhibitors of PKA, which depend in part on 
neurogenic action and activation of GC receptor in the hip-
pocampus (75, 76). There is ample data to support the role of the 
cAMP/PKA pathway in the mediation of antidepressant/anxio-
lytic activity (i.e., rolipram, fluoxetine, and clozapine increase 
cAMP and pCREB expression) in the hippocampus; however, our 
understanding of the specific effects on neurogenesis is evolving.
Studies with Gsα (Gnas) transgenic mice have shown that 
increased cAMP signaling is associated with an anxiety-like 
phenotype (77). Zhang et al. (78) reported that mice with reduced 
PDE 4B activity, the enzyme that degrades cAMP and interrupts 
the negative feedback of PKA pathway resulting in increased PKA 
activity, displayed anxiogenic behavior. In addition, transgenic 
mice with overexpression of the striatially enriched cAMP-
producing adenyl cyclase 5 showed increased anxiety-related 
behavior (79). Results of the studies reviewed above indicate 
that increased cAMP signaling is associated with an anxiety-like 
phenotype, and provide indirect evidence that an increase in PKA 
activity may be associated with an increased risk for anxiety. Also, 
studies of mice with genetic deletion of specific PDE4 subtypes 
have reported anxiogenic behavior, suggesting that PDE4 may be 
involved in the regulation of anxiety (78, 80, 81).
eFFeCT OF PKA DeFeCTS On  
AnXieTY-LiKe BeHAviOR
Prior studies in our lab showed that transgenic mice with a down-
regulated Prkar1a gene (tTA/X2AS, antisense transgene) (82) 
exhibited behavioral abnormalities, including anxiety (83) and 
depression. A KO mouse heterozygous for a null allele of Prkar1a 
was developed in our lab as a model to investigate Carney complex 
that is caused by heterozygous inactivating PRKAR1A mutations 
(84), which results in increased PKA signaling in all cells where 
this gene is expressed. We hypothesized that a transgenic mouse 
model with downregulation of Prkar1a would provide a research 
tool to evaluate the effect of altered PKA expression on anxiety-
like behaviors.
In support of our hypothesis, we found that downregulation 
of the regulatory subunit of PKA in mice led to an augmenta-
tion of anxiety-like behavior supporting the role of PKA in 
modulating anxiety-like behaviors. Compared with WT mice, 
Prkar1a+/− mice had higher basal and stimulated (cAMP) PKA 
activity levels in the central and basolateral amygdala, brain 
areas known to have a critical role in the processing of sensory 
information related to anxiety and emotion as well as regulation 
of arousal level (85).
Since activity in neural circuits prior to or immediately after 
stimuli may influence PKA activity and LTP and, therefore, may 
affect fear learning; we then investigated the rodent defensive 
response in the Prkar1a+/− mouse hypothesizing that Prkar1a+/− 
mice would exhibit an atypical response to threat detection 
(37, 39). As predicted, we found that in contrast to the response 
of WT mice, Prkar1a+/− mice failed to exhibit behavioral changes 
(exploratory or defensive) to distinguish between predator versus 
control odor. The behavioral changes paralleled significant differ-
ences found in PKA activity between WT and Prkar1a+/− mice in 
the amygdala, prefrontal cortex, and ventromedial hypothalamus 
(86). Our findings are consistent with results of electrophysiologi-
cal studies showing that changes in amygdala circuitry and den-
dritic morphology affect fearful responses and correlate with BLA 
transmission and that the degree of anxiogenic effect of predator 
stress is positively associated with the degree of potentiation of 
amygdala circuitry (48, 87, 88). Also, since the function of the 
prefrontal cortex is to inhibit prepotent behavioral and promote 
task relevant behaviors, alterations in PKA activity in the prefron-
tal cortex may also have contributed to the atypical response to 
threat detection in the Prkar1a+/− mice (86).
We introduced half-null alleles of Prkaca+/− into the Prkar1a+/− 
mice, hypothesizing abrogation of the excess Cα activity caused 
by R1α haploinsufficiency. The phenotype of Prkaca+/− mice was 
characterized by attenuation but not elimination of the anxiety 
phenotype noted in Prkar1a heterozygote mice. Measurement 
of PKA activity in various brain areas showed increased PKA 
activity in the amygdala in Prkar1a+/− compared with Prkaca+/− 
or WT, and in part compared with Prkar1a+/−/Prkaca+/− mice. 
The alteration of PKA activity in these transgenic mice was 
not a ubiquitous effect, since PKA activity was found to be 
similar between heterozygotes and WT mice in some brain 
areas (e.g., prefrontal cortex, hippocampus, paraventricular 
hypothalamus, cerebellum, and neural sensory areas). These 
findings highlight the importance of even modest changes in 
PKA activity in modulating anxiety-like behaviors and also 
that catalytic subunit activity is not the sole determinant of 
PKA’s cAMP-signaling effects (89, 90). It is also possible that 
compensatory mechanisms in remaining PKA subunits and 
PDE4 may be a factor in areas not showing any differences in 
PKA activity between Prkar1a+/− and Prkar1a+/−/Prkaca+/− and 
WT or Prkaca+/− mice.
SUMMARY/COnCLUSiOn
In this review, we highlighted the association of abnormal neural 
processing of threat-related stimuli and anxiety disorders, which 
is significantly influenced by the cAMP/PKA pathway, among 
others. Animal models have helped to elucidate the molecular 
pathways that have an important role in anxiety; however, 
there are limitations, so cautious interpretation is appropriate. 
A recently developed mouse of R1a deficiency provides a unique 
model to investigate the direct effect of increased PKA activity on 
the acquisition and expression of learned fear.
Results of clinical studies support the finding that alterations 
in PKA and some of its substrates are associated with various 
psychiatric disorders, including anxiety, depression, obses-
sive–compulsive and bipolar disorders, schizophrenia, and 
panic disorder (91–97). Also, in adult patients with PRKAR1A 
mutations, we reported an increased incidence of psychiatric 
disorders, including anxiety, depression, and bipolar disorder 
(in that order), and for children with PRKAR1A mutations 
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an increased incidence of learning disorders, attention deficit 
hyperactivity disorder, anxiety, and depression (in that order) 
(98). Recent animal studies support the hypothesis that selective 
gene intervention in the cAMP/PKA system may constitute a 
promising anxiolytic target.
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